Palleon Pharmaceuticals is developing drugs for cancer and inflammatory diseases by modulating glycobiology. Cell surface glycans, such as sialoglycans, play an important role in regulating the immune response, with dysregulation linked with several disease disorders. Through the use of their EAGLE platform, Palleon is using engineered human sialidase enzymes to edit glycans and restore antitumor immunity. Palleon’s lead program, E-602, is an genetically engineered protein consisting of a human sialidase with human monoclonal antibodies, designed to desialylate both immune and tumor cells.

Palleon Pharmaceuticals

Founded: 2016
Location: Waltham, MA
Employee range: 1-50
Clinical stage: Clin1
Therapy area: Oncology
Drug types: ONC, IMM
Lead product: E-602
Funding: 100-500M

Drug notes:

About:

Jobs: